Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations

References

• Liu C. C., Manzi S., Ahearn J. M. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005; 17: 543–9
   PubMed Web of Science ®Google Scholar
• Illei G. G., Tackey E., Lapteva L., Lipsky P. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048–65
   PubMed Web of Science ®Google Scholar
• Griffiths B., Mosca M., Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685–708
   PubMed Web of Science ®Google Scholar
• Abel T., Gladman D. D., Urowitz M. B. Neuropsychiatric lupus. J Rheumatol 1980; 7: 325–32
   PubMed Web of Science ®Google Scholar
• Sibley J. T., Olsynski W. P., Decoteau W. E., Sundram M. B. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47–52
   PubMed Web of Science ®Google Scholar
• Cervera R., Khamashta M. A., Font J., Sebastian G. D., Gil A., Lavilla P., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. Medicine 1993; 72: 113–24
   PubMed Web of Science ®Google Scholar
• West S. G. Systemic lupus erythematosus and the nervous system. Dubois lupus erythematosus, 6th edn, D. J Wallace, B. H Hahn. Lippincott Williams & Wilkins, Philadelphia 2002; 693–738
   Google Scholar
• Matsukawa Y., Nagashima M., Kamei S., Tanabe E., Takahashi S., Kojima T., et al. Random number generation evaluation in patients with systemic lupus erythematosus indicates a heterogeneous nature of central nervous system vulnerability. Scand J Rheumatol 2006; 35: 295–9
   PubMed Web of Science ®Google Scholar
• Denburg S. D., Behmann A. S., Carbotte R. M., Denburg J. A. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37: 369–75
   PubMedGoogle Scholar
• Costallat L. T. L., Oliveira R. M., Santiago M. B. Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anticardiolipin, anti‐ganglioside, and anti‐galactocerebrosides in patients with SLE and neurological manifestations. Clin Rheumatol 1990; 9: 489–97
   PubMed Web of Science ®Google Scholar
• Bonfa E., Golombek S. J., Kaufman L. D., Skelly S., Weissbach H., Brot N., et al. Association between lupus psychosis and antiribosomal P protein antibodies. N Engl J Med 1987; 312: 265–71
   Google Scholar
• DeHoratius R. J. Lymphocytotoxic antibodies. Prog Clin Immunol 1980; 4: 151–74
   PubMedGoogle Scholar
• Temesvari P., Denburg J. A., Denburg S. D., Carbotte R., Bensen W., Singal D. Serum lymphocytotoxic antibodies in neuropsychiatric lupus: a serial study. Clin Immunol Immunopathol 1983; 28: 243–51
   PubMedGoogle Scholar
• Denburg S. D., Carbotte R. M., Long A. A., Denburg J. A. Neuropsychological correlates of serum lymphocytotoxic antibodies in systemic lupus erythematosus. Brain Behav Immun 1988; 2: 222–34
   PubMedGoogle Scholar
• Silva L. M., Donadi E. A. Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non‐neuropsychiatric SLE?. Ann Rheum Dis 1996; 55: 544–7
   PubMedGoogle Scholar
• Bluestein H. G., Zvaifler N. J. Brain‐reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 1976; 57: 509–16
   PubMed Web of Science ®Google Scholar
• Bresnihan B. CNS lupus. Clin Rheum Dis 1982; 8: 183–95
   PubMedGoogle Scholar
• Bresnihan B., Grigor R. R., Hughes G. R. V. Lymphocytotoxic antibodies in systemic lupus erythematosus: their clinical significance. J Clin Pathol 1979; 13: 112–15
   Google Scholar
• Bresnihan B., Oliver M., Grigor R., Hughes G. R. V. Brain reactivity of lymphocytotoxic antibodies in systemic lupus erythematosus with and without cerebral involvement. Clin Exp Immunol 1977; 30: 333–7
   PubMedGoogle Scholar
• Long A. A., Denburg S. D., Carbotte R. M., Singal D. P., Denburg J. A. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 249–52
   PubMed Web of Science ®Google Scholar
• Winfield J. B., Brunner C. M., Koffler D. Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 1978; 21: 289–94
   PubMed Web of Science ®Google Scholar
• Levine S. R., Brey R. L. Neurological aspects of antiphospholipid antibody syndrome. Lupus 1996; 5: 347–53
   PubMed Web of Science ®Google Scholar
• Caronti B., Calderaro C., Alessandri C., Conti F., Tinghino R., Palladini G., et al. Beta2‐glycoprotein I mRNA is expressed by several cell types involved in anti‐phospholipid syndrome‐related tissue damage. Clin Exp Immunol 1999; 115: 214–19
   PubMedGoogle Scholar
• Elkon K. B., Parnassa A. P., Foster C. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985; 162: 459–71
   PubMed Web of Science ®Google Scholar
• Stafford H. A., Chen A. E., Anderson C. J., Paul A. G. A., Wyatt E. L., Lee L. A., et al. Anti‐ribosomal and P‐peptide‐specific autoantibodies bind to T lymphocytes. Clin Exp Immunol 1997; 109: 12–19
   PubMedGoogle Scholar
• Winfield J. B. Are anti‐ribosomal P protein antibodies a type of anti‐lymphocyte antibody?. Clin Exp Immunol 1997; 109: 1–3
   PubMedGoogle Scholar
• Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608
   PubMed Web of Science ®Google Scholar
• Liang M. H., Socher S. A., Larson M. G., Schur P. H. Reliability and validity of six systems for the clinical assessment of disease activity in SLE. Arthritis Rheum 1989; 32: 1107–18
   PubMed Web of Science ®Google Scholar
• Gladman D. D., Ibanez D., Urowitz M. B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–91
   PubMed Web of Science ®Google Scholar
• Terasaki P. I., McClelland J., Park M., McCurly B. Microdroplet lymphocyte citotoxicity test. Manual of tissue techniques, J. G Ray, D. B Hare, P. D Pedersen, E Kayhoe. NIH, Bethesda 1974; 66–77
   Google Scholar
• Swaak A. J., Groenwold J., Bronsveld W. Predictive value of complement profiles and anti‐dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359–66
   PubMed Web of Science ®Google Scholar
• Swaak T., Smeenk R. Clinical significance of antibodies to double strand DNA (dsDNA) for systemic lupus erythematosus. Clin Rheumatol 1987; 6: 56–73
   PubMedGoogle Scholar
• Ho A., Magder L. S., Barr S. G., Petri M. Decreases in anti‐double‐stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342–9
   PubMed Web of Science ®Google Scholar
• Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–40
   PubMed Web of Science ®Google Scholar
• Manzi S., Navratil J. S., Ruffing M. J., Liu C. C., Danchenko N., Nilson S. E., et al. Measurement of erythrocyte C4d and complement receptor 1 in the diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3596–604
   PubMed Web of Science ®Google Scholar
• Jacobi A. M., Odendahl M., Reiter K., Bruns A., Burnmester G. R., Radbruch A., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332–42
   PubMed Web of Science ®Google Scholar
• Simon J. A., Cabiedes J., Ortiz E., Alcocer‐Varela J., Sanchez‐Guerrero J. Anti‐nucleosome antibodies in patients with systemic lupus erythematosus of recent onset: potential utility as a diagnostic tool and disease activity marker. Rheumatology 2004; 43: 220–4
   PubMedGoogle Scholar
• Chabre H., Amoura Z., Piette C., Godeau P., Bach J. F., Koutozov S. Presence of nucleosome‐restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1485–91
   PubMedGoogle Scholar
• Min D. J., Kim S. J., Park S. H., Seo Y. I., Kang H. J., Kim W. U., et al. Anti‐nucleosome antibody: significance in lupus patients lacking anti‐double‐stranded DNA antibody. Clin Exp Rheumatol 2002; 20: 13–18
   PubMed Web of Science ®Google Scholar
• Seelen M. A., Trouw L. A., Daha M. R. Diagnostic and prognostic significance of anti‐C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12: 619–24
   PubMed Web of Science ®Google Scholar
• Moroni G., Trendelenburg M., Papa N. D., Quaglini S., Raschi S., Panzeri P., et al. Anti‐C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490–8
   PubMed Web of Science ®Google Scholar
• Oelzner P., Deliyska B., Funfstuck R., Hein G., Herrmann D., Stein G. Anti‐C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus: relationship with disease activity and renal involvement. Clin Rheumatol 2003; 22: 271–8
   PubMed Web of Science ®Google Scholar
• Sjowall C., Bengtsson A. A., Sturfelt G., Skogh T. Serum levels of autoantibodies against monomeric C‐reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6: 87–94
   PubMed Web of Science ®Google Scholar
• Cappione A., Pugh A., Anolik J., Sanz I. Lymphocytotoxic autoantibodies in SLE target a CD45 glycoform preferentially expressed in naïve B‐cells. abstract]. Proceedings of the 65th Annual Scientific Meeting of the American College of Rheumatology; 2001 Nov 11‐15; San Francisco (CA). Poster no. 127. Silva LM, Garcia AB, Donadi EA. Increased lymphocyte death by neglect‐apoptosis is associated with lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations. J Neurol 2002; 249: 1048–54
   PubMedGoogle Scholar
• Hanly J. G., Walsh N. M. G., Sanlang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732–41
   PubMed Web of Science ®Google Scholar
• Schneebaum A. B., Singleton J. D., West S. G., Blodgett J. K., Allen L. G., Cheronis J. C., et al. Association of psychiatric manifestations with antibodies to ribosomal P protein in systemic lupus erythematosus. Am J Med 1991; 90: 54–62
   PubMed Web of Science ®Google Scholar
• Nojima Y., Minota S., Yawanda A., Takaku F., Qotsuka S., Yokoshario R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1053–5
   PubMed Web of Science ®Google Scholar
• Bonfa E., Elkon E. B. Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 1986; 29: 981–5
   PubMed Web of Science ®Google Scholar
• Derksen R. H. W. M., van Dam A. P., Gmelig Meyling F. H. J., Bijlsma J. W., Smeenk R. J. T. A prospective study on antiribosomal P proteins in two cases of familial lupus and recurrent psychosis. Ann Rheum Dis 1990; 49: 779–82
   PubMedGoogle Scholar